Google
XLO — XILIO DEVELOPMENT INC (Healthcare >> Biotechnology)
XLO FAQ
What is XLO's P/E ratio?
XILIO DEVELOPMENT INC (XLO) currently trades at a P/E ratio of 5.06.
What is XLO's ROE?
XILIO DEVELOPMENT INC reports a Return on Equity (ROE) of -43.15%.
What is XLO's dividend yield?
XILIO DEVELOPMENT INC offers a dividend yield of 0.00%.
What is XLO's Deepscope Quality Score?
Deepscope rates XLO's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy XLO?
Deepscope's AI Timing Score for XLO is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does XLO belong to?
XILIO DEVELOPMENT INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 7.70
Price
-0.61
(-7.34%)
Day Change
|
|
|---|
XLO, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 7.70 |
| PBV / Sector |
0.72 / 4.63
GREAT
|
| Earning Per Share | -4.60 |
| PE / Sector |
5.06 / 17.43
GREAT
|
| PEG or PE/Growth / Sector |
0.02 / 0.53
GREAT
|
| Average 1M Daily Value |
0.53 M
GREAT
|
| Average 1W Daily Value |
0.18 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:09:19 |
| Symbol | XLO |
| Name | XILIO DEVELOPMENT INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 6.58 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 52.44 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 828 Winter Street, Waltham, MA, United States, 02451
Phone: 857 524 2466
Website: https://xiliotx.com
Employees: 76
Sector: Healthcare >> Biotechnology
Description: Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
